Recently, a large‐scale multiomics study12 has shown that the difference between HER2 IHC 1+ and IHC 2+ breast cancer in the hormone receptor‐negative subgroup was more significant than in the hormone receptor‐positive subgroup at the levels of the transcriptome, proteome, and metabolome. The gene discussed is ERBB2; the disease is breast carcinoma.